LY2503029

LY2503029 is an orally available small molecule inhibitor developed by Eli Lilly and Company. It acts as a potent inhibitor of the proto-oncogene protein c-akt (also known as Akt), targeting all three isoforms of Akt with low nanomolar potency. The drug was investigated for the treatment of advanced solid tumors, including late-stage and metastatic cancers. As an antineoplastic agent, its mechanism involves inhibition of the Akt signaling pathway, which plays a critical role in cell survival, proliferation, and tumorigenesis. Clinical development included phase I trials and expanded access programs for patients with solid tumors; however, no recent reports indicate ongoing development or advancement beyond early clinical phases[1][2][3].